Table of Content

1    INTRODUCTION    32
1.1    STUDY OBJECTIVES    32
1.2    MARKET DEFINITION    32
1.2.1    INCLUSIONS AND EXCLUSIONS    32
1.3    MARKET SCOPE    33
1.3.1    MARKETS COVERED    33
FIGURE 1    VETERINARY API MARKET SEGMENTATION    33
FIGURE 2    VETERINARY API MARKET, BY REGION    33
1.3.2    YEARS CONSIDERED    34
1.3.3    CURRENCY CONSIDERED    34
1.4    STAKEHOLDERS    35
1.4.1    RECESSION IMPACT    35
2    RESEARCH METHODOLOGY    36
2.1    RESEARCH DATA    36
FIGURE 3    RESEARCH DESIGN    36
2.1.1    SECONDARY DATA    37
2.1.1.1    Key data from secondary sources    38
2.1.2    PRIMARY DATA    38
FIGURE 4    PRIMARY SOURCES    39
2.1.2.1    Key data from primary sources    40
2.1.2.2    Key industry insights    40
FIGURE 5    BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION    41
FIGURE 6    BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION    41
2.2    MARKET SIZE ESTIMATION    42
FIGURE 7    MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS    42
FIGURE 8    REVENUE SHARE ANALYSIS FOR PHIBRO ANIMAL HEALTH CORPORATION (2022)    43
FIGURE 9    VETERINARY API MARKET: SUPPLY-SIDE ANALYSIS (2022)    43
FIGURE 10    VETERINARY API MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES AND THEIR IMPACT ON MARKET GROWTH AND CAGR (2023–2028)    45
FIGURE 11    VETERINARY API MARKET: CAGR PROJECTIONS (2023–2028)    46
2.3    MARKET BREAKDOWN & DATA TRIANGULATION    47
FIGURE 12    DATA TRIANGULATION METHODOLOGY    47
2.4    MARKET SHARE ANALYSIS    47
2.5    RESEARCH ASSUMPTIONS    48
TABLE 1    RESEARCH ASSUMPTIONS    48
2.6    RISK ASSESSMENT    48
2.7    LIMITATIONS    49
2.8    RECESSION IMPACT ANALYSIS    49
3    EXECUTIVE SUMMARY    50
FIGURE 13    VETERINARY API MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)    50
FIGURE 14    VETERINARY API MARKET, BY SYNTHESIS TYPE, 2023 VS. 2028 (USD MILLION)    51
FIGURE 15    VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)    51
FIGURE 16    VETERINARY API MARKET, BY ANIMAL TYPE, 2023 VS. 2028 (USD MILLION)    52
FIGURE 17    VETERINARY API MARKET: GEOGRAPHIC SNAPSHOT, 2022    53
4    PREMIUM INSIGHTS    54
4.1    VETERINARY API MARKET OVERVIEW    54
FIGURE 18    GROWING PREVALENCE OF ANIMAL DISEASES AND RISING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS TO DRIVE MARKET    54
4.2    ASIA PACIFIC: VETERINARY API MARKET, BY TYPE AND COUNTRY (2022)    55
FIGURE 19    PARASITICIDES ACCOUNTED FOR LARGEST SHARE OF APAC VETERINARY API MARKET IN 2022    55
4.3    VETERINARY API MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES    56
FIGURE 20    CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD    56
4.4    VETERINARY API MARKET: REGIONAL MIX    57
FIGURE 21    NORTH AMERICA TO CONTINUE TO DOMINATE VETERINARY API MARKET IN 2022    57
4.5    VETERINARY API MARKET: EMERGING ECONOMIES VS. DEVELOPED COUNTRIES    57
FIGURE 22    EMERGING ECONOMIES TO OFFER GROWTH OPPORTUNITIES TO MARKET PLAYERS DURING FORECAST PERIOD    57
5    MARKET OVERVIEW    58
5.1    INTRODUCTION    58
5.2    MARKET DYNAMICS    58
FIGURE 23    VETERINARY API MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    58
5.2.1    DRIVERS    59
5.2.1.1    Rising incidence of transboundary and zoonotic diseases    59
5.2.1.2    Increasing animal population and pet ownership    59
FIGURE 24    US: INCREASING PET EXPENDITURE, 2010–2021 (USD BILLION)    60
5.2.1.3    Increasing disease control and prevention measures    60
5.2.1.4    Growing demand for animal protein    60
5.2.2    RESTRAINTS    61
5.2.2.1    Regulations restricting use of parasiticides on food-producing animals    61
5.2.2.2    Growing concerns about antibiotic resistance    61
5.2.3    OPPORTUNITIES    62
5.2.3.1    Untapped emerging economies    62
5.2.4    CHALLENGES    62
5.2.4.1    Challenges in large-molecule API synthesis    62
5.2.4.2    High costs of veterinary diagnostics and treatment    62
5.3    INDUSTRY TRENDS    63
5.3.1    GROWING FRAGMENTATION IN VETERINARY API INDUSTRY    63
5.4    PRICING ANALYSIS    63
5.4.1    AVERAGE SELLING PRICE, BY TYPE    63
TABLE 2    AVERAGE SELLING PRICE, BY TYPE (USD)    63
5.4.2    AVERAGE SELLING PRICE TRENDS    63
5.5    SUPPLY CHAIN ANALYSIS    64
FIGURE 25    SUPPLY CHAIN ANALYSIS: VETERINARY API MARKET    65
5.6    ECOSYSTEM ANALYSIS    65
FIGURE 26    ECOSYSTEM ANALYSIS: VETERINARY API MARKET    65
5.7    PATENT ANALYSIS    66
FIGURE 27    PATENT PUBLICATION TRENDS (JANUARY 2013–MAY 2023)    66
5.7.1    TOP APPLICANTS (COMPANIES/INSTITUTES)    66
FIGURE 28    VETERINARY API MARKET: TOP APPLICANTS (COMPANIES/INSTITUTES) FOR PATENTS (2013–2023)    66
5.8    VALUE CHAIN ANALYSIS    67
FIGURE 29    VALUE CHAIN ANALYSIS: VETERINARY API MARKET    67
5.9    CASE STUDIES    68
5.9.1    IDENTIFYING BUSINESS OPPORTUNITIES IN BROAD-SPECTRUM PARASITICIDES, US    68
5.10    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS    69
TABLE 3    NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS    69
TABLE 4    EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS    70
TABLE 5    ASIA PACIFIC AND ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS    71
5.11    PORTER’S FIVE FORCES ANALYSIS    72
TABLE 6    PORTER’S FIVE FORCES ANALYSIS: VETERINARY API MARKET    72
5.11.1    INTENSITY OF COMPETITIVE RIVALRY    72
5.11.2    BARGAINING POWER OF SUPPLIERS    72
5.11.3    BARGAINING POWER OF BUYERS    72
5.11.4    THREAT OF NEW ENTRANTS    73
5.11.5    THREAT OF SUBSTITUTES    73
5.12    ADJACENT MARKET ANALYSIS    74
FIGURE 30    ANIMAL ANTIBIOTICS AND ANTIMICROBIALS MARKET: MARKET OVERVIEW    74
5.13    KEY CONFERENCES & EVENTS IN 2023–2024    75
TABLE 7    VETERINARY API MARKET: DETAILED LIST OF CONFERENCES AND EVENTS    75
5.14    KEY STAKEHOLDERS AND BUYING CRITERIA    76
5.14.1    KEY STAKEHOLDERS IN BUYING PROCESS    76
FIGURE 31    INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE API TYPES    76
TABLE 8    INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE API TYPES    76
5.14.2    BUYING CRITERIA    77
TABLE 9    KEY BUYING CRITERIA FOR TOP THREE API TYPES    77
5.15    TRADE ANALYSIS    78
TABLE 10    TOP 10 IMPORTERS OF ANTIBIOTICS (HS CODE–2941)    78
TABLE 11    TOP 10 EXPORTERS OF ANTIBIOTICS (HS CODE–2941)    78
TABLE 12    TOP 10 IMPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE–2937)    79
TABLE 13    TOP 10 EXPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE–2937)    79
5.16    IMPACT OF RECESSION ON VETERINARY API MARKET    80
6    VETERINARY API MARKET, BY TYPE    81
6.1    INTRODUCTION    82
TABLE 14    VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    82
6.2    PARASITICIDES    82
TABLE 15    PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    83
TABLE 16    PARASITICIDES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    83
6.2.1    ALBENDAZOLE & FENBENDAZOLE    84
6.2.1.1    Growing prevalence of infections in animals to boost adoption    84
TABLE 17    ALBENDAZOLE & FENBENDAZOLE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    84
6.2.2    IVERMECTIN    85
6.2.2.1    Effectiveness in treating parasitic infections to drive market    85
TABLE 18    IVERMECTIN MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    85
6.2.3    PRAZIQUANTEL    86
6.2.3.1    Growing resistance to other treatment options to drive demand    86
TABLE 19    PRAZIQUANTEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    86
6.2.4    LEVAMISOLE    87
6.2.4.1    Cost-effectiveness to drive usage in parasitic infection treatment    87
TABLE 20    LEVAMISOLE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    87
6.2.5    OTHER PARASITICIDES    88
TABLE 21    OTHER PARASITICIDES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    88
6.3    VACCINES    89
TABLE 22    VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    89
TABLE 23    VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    90
6.3.1    CANINE PARVOVIRUS & CANINE DISTEMPER VIRUS VACCINES    91
6.3.1.1    Availability of effective vaccines against highly contagious diseases to drive market    91
TABLE 24    CPV & CDV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    91
6.3.2    NEWCASTLE DISEASE VIRUS VACCINES    92
6.3.2.1    Need to ensure poultry health to boost vaccine usage    92
TABLE 25    NDV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    92
6.3.3    INFECTIOUS BURSAL DISEASE VIRUS VACCINES    93
6.3.3.1    Veterinarian recommendations to drive vaccine demand    93
TABLE 26    IBDV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    93
6.3.4    FELINE LEUKEMIA VIRUS VACCINES    94
6.3.4.1    Rising feline population to drive market    94
TABLE 27    FELV VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    94
6.3.5    OTHER VACCINES    95
TABLE 28    OTHER VACCINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    95
6.4    ANTIMICROBIALS    96
TABLE 29    ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    96
TABLE 30    ANTIMICROBIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    96
6.4.1    BETA-LACTAMS    97
6.4.1.1    Rising incidence of zoonotic diseases in livestock to drive demand for beta-lactams    97
TABLE 31    BETA-LACTAMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    97
6.4.2    TETRACYCLINES    98
6.4.2.1    Decreasing prices to support demand growth    98
TABLE 32    TETRACYCLINES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    98
6.4.3    AMINOGLYCOSIDES    99
6.4.3.1    Growing food-producing animal population to boost demand    99
TABLE 33    AMINOGLYCOSIDES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    99
6.4.4    FLUOROQUINOLONES    100
6.4.4.1    Compatibility with different routes of administration to ensure sustained market growth    100
TABLE 34    FLUOROQUINOLONES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    100
6.4.5    OTHER ANTIMICROBIALS    101
TABLE 35    OTHER ANTIMICROBIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    101
6.5    ANTI-INFLAMMATORIES    102
TABLE 36    ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    102
TABLE 37    ANTI-INFLAMMATORIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    103
6.5.1    MELOXICAM & PIROXICAM    104
6.5.1.1    Relatively low side-effect profiles to drive market growth    104
TABLE 38    MELOXICAM & PIROXICAM MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    104
6.5.2    CARPROFEN    105
6.5.2.1    Wide treatment applications to drive market    105
TABLE 39    CARPROFEN MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    105
6.5.3    DERACOXIB & FIROCOXIB    106
6.5.3.1    Effectiveness in pain relief and inflammation to boost demand    106
TABLE 40    DERACOXIB & FIROCOXIB MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    106
6.5.4    OTHER ANTI-INFLAMMATORIES    107
TABLE 41    OTHER ANTI-INFLAMMATORIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    107
6.6    HORMONES    108
TABLE 42    HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    108
TABLE 43    HORMONES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    108
6.6.1    PROGESTERONE & TESTOSTERONE    109
6.6.1.1    Progesterone & testosterone to hold largest share of hormones market over forecast period    109
TABLE 44    PROGESTERONE & TESTOSTERONE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    109
6.6.2    ESTRADIOL    110
6.6.2.1    Wide applications in regulating animal reproductive functions to drive market    110
TABLE 45    ESTRADIOL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    110
6.6.3    LUTEINIZING HORMONE    111
6.6.3.1    Wide usage in assisted reproduction to ensure continued demand    111
TABLE 46    LUTEINIZING HORMONE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    111
6.6.4    OTHER HORMONES    112
TABLE 47    OTHER HORMONES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    112
6.7    OTHER VETERINARY APIS    113
TABLE 48    OTHER VETERINARY APIS, BY COUNTRY, 2021–2028 (USD MILLION)    113
7    VETERINARY API MARKET, BY SYNTHESIS TYPE    114
7.1    INTRODUCTION    115
TABLE 49    VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    115
7.2    CHEMICAL-BASED API    116
7.2.1    CHEMICAL-BASED API TO HOLD LARGEST SHARE OVER FORECAST PERIOD    116
TABLE 50    CHEMICAL-BASED VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    116
7.3    BIOLOGICAL API    117
7.3.1    GROWING INDUSTRY RECOGNITION TO DRIVE FOCUS ON BIOLOGICAL API PRODUCTION    117
TABLE 51    BIOLOGICAL VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    117
7.4    HIGHLY POTENT API    118
7.4.1    RISING NEED FOR ADVANCED TREATMENT AND IMPROVED OUTCOMES TO DRIVE MARKET    118
TABLE 52    HIGHLY POTENT VETERINARY API MARKET, BY COUNTRY 2021–2028 (USD MILLION)    118

8    VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION    119
8.1    INTRODUCTION    120
TABLE 53    VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    120
8.2    ORAL    120
8.2.1    CONVENIENCE AND EASE OF ADMINISTRATION TO SUSTAIN DEMAND    120
TABLE 54    ORAL VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    121
8.3    INJECTABLE    121
8.3.1    RAPID ONSET OF ACTION AND PRECISE DOSAGE AND DELIVERY TO BOOST DEMAND FOR INJECTABLES    121
TABLE 55    INJECTABLE VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    122
8.4    TOPICAL    122
8.4.1    OPTIMIZED, TARGETED DELIVERY CAPABILITIES TO DRIVE GROWTH    122
TABLE 56    TOPICAL VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    123
8.5    OTHER ROUTES    123
TABLE 57    VETERINARY API MARKET FOR OTHER ROUTES, BY COUNTRY, 2021–2028 (USD MILLION)    124
9    VETERINARY API MARKET, BY ANIMAL TYPE    125
9.1    INTRODUCTION    126
TABLE 58    VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    126
9.2    COMPANION ANIMALS    126
9.2.1    COMPANION ANIMALS SEGMENT TO DOMINATE MARKET, BY ANIMAL TYPE    126
TABLE 59    VETERINARY API MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2021–2028 (USD MILLION)    127
9.3    LIVESTOCK ANIMALS    127
9.3.1    FOCUS ON OPTIMIZING PRODUCTION AND PREVENTING OUTBREAKS TO DRIVE MARKET    127
TABLE 60    VETERINARY API MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2021–2028 (USD MILLION)    128
10    VETERINARY API MARKET, BY REGION    129
10.1    INTRODUCTION    130
FIGURE 32    VETERINARY API MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES    130
TABLE 61    VETERINARY API MARKET, BY REGION, 2021–2028 (USD MILLION)    131
TABLE 62    VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    131
10.2    NORTH AMERICA    132
FIGURE 33    NORTH AMERICA: VETERINARY API MARKET SNAPSHOT    133
10.2.1    NORTH AMERICA: RECESSION IMPACT    134
TABLE 63    NORTH AMERICA: VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    134
TABLE 64    NORTH AMERICA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    134
TABLE 65    NORTH AMERICA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    135
TABLE 66    NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    135
TABLE 67    NORTH AMERICA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    135
TABLE 68    NORTH AMERICA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    136
TABLE 69    NORTH AMERICA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    136
TABLE 70    NORTH AMERICA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    136
TABLE 71    NORTH AMERICA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    137
TABLE 72    NORTH AMERICA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    137
10.2.2    US    137
10.2.2.1    Growing demand for veterinary APIs to drive market    137
TABLE 73    US: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    138
TABLE 74    US: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    138
TABLE 75    US: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    139
TABLE 76    US: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    139
TABLE 77    US: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    139
TABLE 78    US: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    140
TABLE 79    US: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    140
TABLE 80    US: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    140
TABLE 81    US: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    141
10.2.3    CANADA    141
10.2.3.1    Increasing number of pets in Canada to boost the market    141
TABLE 82    CANADA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    141
TABLE 83    CANADA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    142
TABLE 84    CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    142
TABLE 85    CANADA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    142
TABLE 86    CANADA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    143
TABLE 87    CANADA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    143
TABLE 88    CANADA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    143
TABLE 89    CANADA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    144
TABLE 90    CANADA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    144

10.3    EUROPE    145
10.3.1    EUROPE: RECESSION IMPACT    145
TABLE 91    EUROPE: VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    145
TABLE 92    EUROPE: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    146
TABLE 93    EUROPE: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    146
TABLE 94    EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    147
TABLE 95    EUROPE: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    147
TABLE 96    EUROPE: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    147
TABLE 97    EUROPE: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    148
TABLE 98    EUROPE: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    148
TABLE 99    EUROPE: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    148
TABLE 100    EUROPE: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    149
10.3.2    GERMANY    149
10.3.2.1    Germany to hold largest market share in Europe    149
TABLE 101    GERMANY: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    149
TABLE 102    GERMANY: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    150
TABLE 103    GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    150
TABLE 104    GERMANY: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    150
TABLE 105    GERMANY: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    151
TABLE 106    GERMANY: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    151
TABLE 107    GERMANY: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    151
TABLE 108    GERMANY: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    152
TABLE 109    GERMANY: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    152
10.3.3    FRANCE    152
10.3.3.1    Strong animal welfare regulations to drive market    152
TABLE 110    FRANCE: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    153
TABLE 111    FRANCE: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    153
TABLE 112    FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    154
TABLE 113    FRANCE: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    154
TABLE 114    FRANCE: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    154
TABLE 115    FRANCE: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    155
TABLE 116    FRANCE: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    155
TABLE 117    FRANCE: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    155
TABLE 118    FRANCE: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    156
10.3.4    UK    156
10.3.4.1    Focus on preventive care to drive market    156
TABLE 119    UK: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    156
TABLE 120    UK: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    157
TABLE 121    UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    157
TABLE 122    UK: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    157
TABLE 123    UK: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    158
TABLE 124    UK: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    158
TABLE 125    UK: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    158
TABLE 126    UK: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    159
TABLE 127    UK: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    159
10.3.5    ITALY    159
10.3.5.1    Increasing prevalence of animal diseases to drive market    159
TABLE 128    ITALY: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    160
TABLE 129    ITALY: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    160
TABLE 130    ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    161
TABLE 131    ITALY: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    161
TABLE 132    ITALY: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    161
TABLE 133    ITALY: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    162
TABLE 134    ITALY: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    162
TABLE 135    ITALY: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    162
TABLE 136    ITALY: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    163
10.3.6    SPAIN    163
10.3.6.1    Growing focus on animal health in Spain to support growth    163
TABLE 137    SPAIN: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    163
TABLE 138    SPAIN: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    164
TABLE 139    SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    164
TABLE 140    SPAIN: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    164
TABLE 141    SPAIN: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    165
TABLE 142    SPAIN: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    165
TABLE 143    SPAIN: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    165
TABLE 144    SPAIN: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    166
TABLE 145    SPAIN: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    166
10.3.7    REST OF EUROPE    166
TABLE 146    REST OF EUROPE: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    167
TABLE 147    REST OF EUROPE: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    167
TABLE 148    REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    168
TABLE 149    REST OF EUROPE: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    168
TABLE 150    REST OF EUROPE: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    168
TABLE 151    REST OF EUROPE: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    169
TABLE 152    REST OF EUROPE: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    169
TABLE 153    REST OF EUROPE: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    169
TABLE 154    REST OF EUROPE: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    170
10.4    ASIA PACIFIC    170
FIGURE 34    ASIA PACIFIC: VETERINARY API MARKET SNAPSHOT    171
10.4.1    ASIA PACIFIC: RECESSION IMPACT    172
TABLE 155    ASIA PACIFIC: VETERINARY API MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    172
TABLE 156    ASIA PACIFIC: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    172
TABLE 157    ASIA PACIFIC: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    173
TABLE 158    ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    173
TABLE 159    ASIA PACIFIC: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    173
TABLE 160    ASIA PACIFIC: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    174
TABLE 161    ASIA PACIFIC: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    174
TABLE 162    ASIA PACIFIC: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    174
TABLE 163    ASIA PACIFIC: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    175
TABLE 164    ASIA PACIFIC: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    175
10.4.2    CHINA    175
10.4.2.1    China to retain market leadership in APAC over forecast period    175
TABLE 165    CHINA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    176
TABLE 166    CHINA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    176
TABLE 167    CHINA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    177
TABLE 168    CHINA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    177
TABLE 169    CHINA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    177
TABLE 170    CHINA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    178
TABLE 171    CHINA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    178
TABLE 172    CHINA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    178
TABLE 173    CHINA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    179
10.4.3    JAPAN    179
10.4.3.1    Growing pet ownership and companion animal care to drive market    179
TABLE 174    JAPAN: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    179
TABLE 175    JAPAN: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    180
TABLE 176    JAPAN: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    180
TABLE 177    JAPAN: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    180
TABLE 178    JAPAN: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    181
TABLE 179    JAPAN: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    181
TABLE 180    JAPAN: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    181
TABLE 181    JAPAN: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    182
TABLE 182    JAPAN: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    182
10.4.4    INDIA    182
10.4.4.1    Expanding livestock industry and prevalence of veterinary diseases to support growth    182
TABLE 183    INDIA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    183
TABLE 184    INDIA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    183
TABLE 185    INDIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    184
TABLE 186    INDIA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    184
TABLE 187    INDIA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    184
TABLE 188    INDIA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    185
TABLE 189    INDIA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    185
TABLE 190    INDIA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    185
TABLE 191    INDIA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    186
10.4.5    SOUTH KOREA    186
10.4.5.1    Increasing awareness of animal health to drive market    186
TABLE 192    SOUTH KOREA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    186
TABLE 193    SOUTH KOREA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    187
TABLE 194    SOUTH KOREA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    187
TABLE 195    SOUTH KOREA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    187
TABLE 196    SOUTH KOREA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    188
TABLE 197    SOUTH KOREA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    188
TABLE 198    SOUTH KOREA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    188
TABLE 199    SOUTH KOREA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    189
TABLE 200    SOUTH KOREA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    189
10.4.6    AUSTRALIA    189
10.4.6.1    Well-developed veterinary services in Australia to drive market    189
TABLE 201    AUSTRALIA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    190
TABLE 202    AUSTRALIA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    190
TABLE 203    AUSTRALIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    191
TABLE 204    AUSTRALIA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    191
TABLE 205    AUSTRALIA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    191
TABLE 206    AUSTRALIA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    192
TABLE 207    AUSTRALIA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    192
TABLE 208    AUSTRALIA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    192
TABLE 209    AUSTRALIA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    193
10.4.7    REST OF ASIA PACIFIC    193
TABLE 210    REST OF ASIA PACIFIC: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    193
TABLE 211    REST OF ASIA PACIFIC: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    194
TABLE 212    REST OF ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    194
TABLE 213    REST OF ASIA PACIFIC: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    194
TABLE 214    REST OF ASIA PACIFIC: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    195
TABLE 215    REST OF ASIA PACIFIC: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    195
TABLE 216    REST OF ASIA PACIFIC: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    195
TABLE 217    REST OF ASIA PACIFIC: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    196
TABLE 218    REST OF ASIA PACIFIC: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    196
10.5    LATIN AMERICA    197
10.5.1    RISING LIVESTOCK AND COMPANION ANIMAL POPULATION TO BOOST DEMAND    197
10.5.2    LATIN AMERICA: RECESSION IMPACT    197
TABLE 219    LATIN AMERICA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    197
TABLE 220    LATIN AMERICA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    198
TABLE 221    LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    198
TABLE 222    LATIN AMERICA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    198
TABLE 223    LATIN AMERICA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    199
TABLE 224    LATIN AMERICA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    199
TABLE 225    LATIN AMERICA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    199
TABLE 226    LATIN AMERICA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    200
TABLE 227    LATIN AMERICA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    200
10.6    MIDDLE EAST & AFRICA    200
10.6.1    RISING INCIDENCE OF PARASITIC INFECTIONS TO DRIVE DEMAND FOR TREATMENTS    200
10.6.2    MIDDLE EAST & AFRICA: RECESSION IMPACT    201
TABLE 228    MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY TYPE, 2021–2028 (USD MILLION)    201
TABLE 229    MIDDLE EAST & AFRICA: PARASITICIDES MARKET, BY TYPE, 2021–2028 (USD MILLION)    201
TABLE 230    MIDDLE EAST & AFRICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD MILLION)    202
TABLE 231    MIDDLE EAST & AFRICA: ANTIMICROBIALS MARKET, BY TYPE, 2021–2028 (USD MILLION)    202
TABLE 232    MIDDLE EAST & AFRICA: ANTI-INFLAMMATORIES MARKET, BY TYPE, 2021–2028 (USD MILLION)    202
TABLE 233    MIDDLE EAST & AFRICA: HORMONES MARKET, BY TYPE, 2021–2028 (USD MILLION)    203
TABLE 234    MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY SYNTHESIS TYPE, 2021–2028 (USD MILLION)    203
TABLE 235    MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)    203
TABLE 236    MIDDLE EAST & AFRICA: VETERINARY API MARKET, BY ANIMAL TYPE, 2021–2028 (USD MILLION)    204
11    COMPETITIVE LANDSCAPE    205
11.1    OVERVIEW    205
11.2    KEY PLAYER STRATEGIES    205
FIGURE 35    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY API MARKET    206
11.3    REVENUE SHARE ANALYSIS OF KEY PLAYERS    206
FIGURE 36    REVENUE ANALYSIS FOR KEY PLAYERS IN VETERINARY API MARKET    207
11.4    MARKET SHARE ANALYSIS    207
FIGURE 37    VETERINARY API MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022    208
TABLE 237    VETERINARY API MARKET: DEGREE OF COMPETITION    209
11.5    COMPANY EVALUATION MATRIX, 2022    210
11.5.1    STARS    210
11.5.2    PERVASIVE PLAYERS    210
11.5.3    EMERGING LEADERS    210
11.5.4    PARTICIPANTS    210
FIGURE 38    VETERINARY API MARKET: COMPANY EVALUATION MATRIX, 2022    211
11.6    COMPETITIVE BENCHMARKING    212
TABLE 238    OVERALL COMPANY FOOTPRINT    212
TABLE 239    COMPANY FOOTPRINT ANALYSIS, BY TYPE    213
TABLE 240    COMPANY FOOTPRINT ANALYSIS, BY SYNTHESIS TYPE    214
TABLE 241    COMPANY FOOTPRINT ANALYSIS, BY ROUTE OF ADMINISTRATION    215
TABLE 242    COMPANY FOOTPRINT ANALYSIS, BY ANIMAL TYPE    217
TABLE 243    COMPANY FOOTPRINT ANALYSIS, BY REGION    218
11.7    COMPETITIVE SCENARIO    219
11.7.1    PRODUCT LAUNCHES & APPROVALS    219
TABLE 244    PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2023    219
11.7.2    DEALS    219
TABLE 245    DEALS, JANUARY 2021–MAY 2023    219
11.7.3    OTHER DEVELOPMENTS    220
TABLE 246    OTHER DEVELOPMENTS, JANUARY 2019- MAY 2023    220"    "12    COMPANY PROFILES    221
12.1    KEY PLAYERS    221
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1    BOEHRINGER INGELHEIM GMBH    221
TABLE 247    BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW    221
FIGURE 39    BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2022)    222
12.1.2    ZOETIS, INC.    225
TABLE 248    ZOETIS, INC.: BUSINESS OVERVIEW    225
FIGURE 40    ZOETIS, INC.: COMPANY SNAPSHOT (2022)    226
12.1.3    ELANCO ANIMAL HEALTH INCORPORATED    228
TABLE 249    ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW    228
FIGURE 41    ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2022)    228
12.1.4    MERCK & CO., INC.    231
TABLE 250    MERCK & CO., INC.: BUSINESS OVERVIEW    231
FIGURE 42    MERCK & CO., INC.: COMPANY SNAPSHOT (2022)    232
12.1.5    VIRBAC    235
TABLE 251    VIRBAC: BUSINESS OVERVIEW    235
FIGURE 43    VIRBAC: COMPANY SNAPSHOT (2022)    236
12.1.6    VETOQUINOL S.A.    238
TABLE 252    VETOQUINOL S.A.: BUSINESS OVERVIEW    238
FIGURE 44    VETOQUINOL S.A.: COMPANY SNAPSHOT (2022)    238
12.1.7    SEQUENT SCIENTIFIC LIMITED    240
TABLE 253    SEQUENT SCIENTIFIC LIMITED: BUSINESS OVERVIEW    240
FIGURE 45    SEQUENT SCIENTIFIC LIMITED: COMPANY SNAPSHOT (2022)    241
12.1.8    PHIBRO ANIMAL HEALTH CORPORATION    243
TABLE 254    PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW    243
FIGURE 46    PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2022)    244
12.1.9    FABBRICA ITALIANA SINTETICI S.P.A.    246
TABLE 255    FABBRICA ITALIANA SINTETICI: BUSINESS OVERVIEW    246
FIGURE 47    FABBRICA ITALIANA SINTETICI: COMPANY SNAPSHOT (2022)    246
12.1.10    EXCEL INDUSTRIES LTD.    248
TABLE 256    EXCEL INDUSTRIES LTD.: BUSINESS OVERVIEW    248
FIGURE 48    EXCEL INDUSTRIES LTD.: COMPANY SNAPSHOT (2022)    249
12.1.11    NGL FINE-CHEM LTD.    251
TABLE 257    NGL FINE-CHEM: BUSINESS OVERVIEW    251
FIGURE 49    NGL FINE-CHEM: COMPANY SNAPSHOT (2022)    251
12.1.12    QILU PHARMACEUTICAL    254
TABLE 258    QILU PHARMACEUTICAL: BUSINESS OVERVIEW    254
12.1.13    OLON S.P.A.    256
TABLE 259    OLON S.P.A: BUSINESS OVERVIEW    256
12.1.14    SHANDONG LUKANG PHARMACEUTICAL CO., LTD.    258
TABLE 260    SHANDONG LUKANG PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW    258
12.1.15    ZHEJIANG HUADI PHARMACEUTICAL GROUP CO., LTD.    259
TABLE 261    ZHEJIANG HUADI PHARMACEUTICAL GROUP CO., LTD.: BUSINESS OVERVIEW    259
12.1.16    INSUD PHARMA    260
TABLE 262    INSUD PHARMA: BUSINESS OVERVIEW    260
12.1.17    MENADIONA SL    261
TABLE 263    MENADIONA SL: BUSINESS OVERVIEW    261
12.1.18    ROCHEM INTERNATIONAL, INC.    262
TABLE 264    ROCHEM INTERNATIONAL: BUSINESS OVERVIEW    262
12.1.19    AFTON PHARMA    264
TABLE 265    LIMITED AFTON PHARMA: BUSINESS OVERVIEW    264
12.1.20    SHAANXI HANJIANG PHARMACEUTICAL GROUP CO. LTD.    265
TABLE 266    SHAANXI HANJIANG PHARMACEUTICAL GROUP CO. LTD.: BUSINESS OVERVIEW    265
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2    OTHER PLAYERS    266
12.2.1    DALIAN LAUNCHER FINE CHEMICAL CO., LTD.    266
12.2.2    AMGIS LIFESCIENCE LTD.    267
12.2.3    D.H. ORGANICS    267
12.2.4    SIFLON DRUGS    268
12.2.5    SBD HEALTHCARE PVT. LTD.    268
12.2.6    CENTURY PHARMACEUTICALS LTD.    269
12.2.7    SIDHIV PHARMA    270
12.2.8    FERMION    271
12.2.9    CHEMINO PHARMA PRIVATE LIMITED    271
12.2.10    SUANFARMA    272
13    APPENDIX    273
13.1    DISCUSSION GUIDE    273
13.2    KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    277
13.3    RELATED REPORTS    279
13.4    AUTHOR DETAILS    280